NewAmsterdam Pharma Company N.V.NAMSNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank20
3Y CAGR-40.7%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-40.7%/yr
Annual compound
Percentile
P20
Within normal range
vs 3Y Ago
0.2x
Contraction
Streak
3 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 50.89% |
| 2024 | 87.19% |
| 2023 | 92.92% |
| 2022 | 243.61% |
| 2021 | 235.78% |
| 2020 | 0.00% |